Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial
The proportion of patients who met improvement criteria after 24 weeks was similar between abatacept and placebo groups. However, analysis by IIM subtype suggested there may be a sustained benefit of SC abatacept for patients with non-DM subtypes.
Authors
- Ingrid E. Lundberg (ORCID: https://orcid.org/0000-0002-6068-9212)
- Rohit Aggarwal (ORCID: https://orcid.org/0000-0001-7531-8038)
- Victoria P. Werth (ORCID: https://orcid.org/0000-0003-3030-5369)
- Yeong Wook Song (ORCID: https://orcid.org/0000-0002-5384-3437)
- Aziz Shaibani (ORCID: https://orcid.org/0000-0001-9828-0861)
- Michael A. Maldonado (ORCID: https://orcid.org/0009-0007-4391-2324)
Institutions
- Karolinska University Hospital (SE)
- Seoul National University (KR)
- Bristol-Myers Squibb (Germany) (DE)
- University of Pittsburgh (US)
- Karolinska Institutet (SE)
- Bristol-Myers Squibb (United States) (US)
- Nerve Centre (GB)
- Bristol-Myers Squibb (Sweden) (SE)
- Texas Nerve and Paralysis Institute (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1002/art.43066
- Citations
- 14
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 5.41
Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- CSL Behring
- Regeneron Pharmaceuticals
- Argenx
- National Institutes of Health
- Genentech
- EMD Serono